SCHEMBL29947996

SCHEMBL29947996

FC(F)(F)c1nc(Cl)c2oc3ccccc3c2n1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.54
HRH4 Q9H3N8 2/20 0.44
KMT2A Q03164 5/20 0.43
MEN1 O00255 4/20 0.43
ALDH1A1 P00352 3/20 0.43
KDM4E B2RXH2 1/20 0.43
PIM1 P11309 2/20 0.42
CSNK2A2 P19784 2/20 0.42
CSNK2B P67870 2/20 0.42
PIM3 Q86V86 2/20 0.42
PIM2 Q9P1W9 2/20 0.42
CYP1A2 P05177 1/20 0.41
CYP2C19 P33261 1/20 0.41
MAPT P10636 2/20 0.40
ADORA2A P29274 1/20 0.39
LMNA P02545 2/20 0.39
POLB P06746 1/20 0.39
GLA P06280 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
LIMK1 P53667 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24843012 1.00 SMN1; SMN2 (0.54) SMN1; SMN2HRH4KMT2AMEN1ALDH1A1
SCHEMBL24845794 0.90 SMN1; SMN2 (0.53) SMN1; SMN2KMT2AMEN1ALDH1A1KDM4E
SCHEMBL24846116 0.88 SMN1; SMN2 (0.51) SMN1; SMN2KMT2AMEN1ALDH1A1KDM4E
SCHEMBL24846161 0.88 SMN1; SMN2 (0.51) SMN1; SMN2KMT2AMEN1ALDH1A1KDM4E
SCHEMBL31673315 0.86 SMN1; SMN2 (0.55) SMN1; SMN2HRH4KMT2AMEN1ALDH1A1
SCHEMBL4593581 0.82 HRH4 (0.62) HRH4KMT2AMEN1ALDH1A1PIM1
SCHEMBL1310612 0.79 SMN1; SMN2 (0.62) SMN1; SMN2KMT2AMEN1ALDH1A1KDM4E
SCHEMBL30960342 0.79 SMN1; SMN2 (0.42) SMN1; SMN2KMT2AMEN1ALDH1A1KDM4E
SCHEMBL2217397 0.78 SMN1; SMN2 (0.47) SMN1; SMN2KMT2AMEN1ALDH1A1KDM4E
SCHEMBL15304530 0.78 KMT2A (0.62) SMN1; SMN2HRH4KMT2AMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250360141-A1 PYRIDINE DERIVATIVES WITH N-LINKED CYCLIC SUBSTITUENTS AS cGAS INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2025-11-27 US disclosed
WO-2025233174-A1 BENZIMIDAZOLE DERIVATIVES AS CGAS INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2025-11-13 WO disclosed
US-12433897-B2 Pyridine derivatives with n-linked cyclic substituents as cGAS inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2025-10-07 US disclosed
US-20240342186-A1 PYRIDINE DERIVATIVES WITH N-LINKED CYCLIC SUBSTITUENTS AS cGAS INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2024-10-17 US disclosed
US-12043625-B2 Pyridine derivatives with c-linked cyclic substituents as cGAS inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2024-07-23 US disclosed
EP-4337327-A1 PYRIDINE DERIVATIVES WITH C-LINKED CYCLIC SUBSTITUENTS AS CGAS INHIBITORS Boehringer Ingelheim International GmbH (DE) 2024-03-20 EP disclosed
EP-4337326-A1 PYRIDINE DERIVATIVES WITH N-LINKED CYCLIC SUBSTITUENTS AS CGAS INHIBITORS Boehringer Ingelheim International GmbH (DE) 2024-03-20 EP disclosed
US-20230002401-A1 PYRIDINE DERIVATIVES WITH C-LINKED CYCLIC SUBSTITUENTS AS cGAS INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2023-01-05 US disclosed
US-20230000878-A1 PYRIDINE DERIVATIVES WITH N-LINKED CYCLIC SUBSTITUENTS AS cGAS INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2023-01-05 US disclosed
WO-2022238335-A1 PYRIDINE DERIVATIVES WITH C-LINKED CYCLIC SUBSTITUENTS AS CGAS INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2022-11-17 WO disclosed
WO-2022238327-A1 PYRIDINE DERIVATIVES WITH N-LINKED CYCLIC SUBSTITUENTS AS CGAS INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2022-11-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12043625-B2 Pyridine derivatives with c-linked cyclic substituents as cGAS inhibitors CGAS, GLS2, GMPS SMN1; SMN2 2442/4885HRH4 1006/4885KMT2A 4817/4885
US-20230002401-A1 PYRIDINE DERIVATIVES WITH C-LINKED CYCLIC SUBSTITUENTS AS cGAS INHIBITORS CGAS, GLS2, GMPS SMN1; SMN2 2442/4885HRH4 1006/4885KMT2A 4817/4885
US-20240342186-A1 PYRIDINE DERIVATIVES WITH N-LINKED CYCLIC SUBSTITUENTS AS cGAS INHIBITORS CGAS, GLS2, GMPS SMN1; SMN2 2556/4885HRH4 707/4885KMT2A 4804/4885
US-20250360141-A1 PYRIDINE DERIVATIVES WITH N-LINKED CYCLIC SUBSTITUENTS AS cGAS INHIBITORS CGAS, GLS2, GMPS SMN1; SMN2 2437/4885HRH4 646/4885KMT2A 4814/4885
US-20230000878-A1 PYRIDINE DERIVATIVES WITH N-LINKED CYCLIC SUBSTITUENTS AS cGAS INHIBITORS CGAS, GLS2, GMPS SMN1; SMN2 2556/4885HRH4 707/4885KMT2A 4804/4885
US-12433897-B2 Pyridine derivatives with n-linked cyclic substituents as cGAS inhibitors CGAS, GLS2, GMPS SMN1; SMN2 2556/4885HRH4 707/4885KMT2A 4804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.